Leona Health | $14,000,000 | (Dec 18, 2025)
Limenet | $8,217,860 | (Dec 18, 2025)
Codoxo | $35,000,000 | (Dec 18, 2025)
Certified by Founder
Lodge
Braveheart Bio
start up
United States
- San Francisco, California
- 06/11/2025
- Series A
- $185,000,000
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science investors including Andreessen Horowitz (a16z Bio + Health), Forbion, OrbiMed, Enavate Sciences (a platform of Patient Square Capital), and Frazier Life Sciences. Braveheart is advancing BHB-1893 through late-stage clinical development with the goal of establishing a new standard of care.
- Industry Biotechnology Research
- Website https://www.braveheart.bio/
- LinkedIn https://www.linkedin.com/company/braveheart-bio/
Drive Health | $15,000,000 | (Dec 18, 2025)
DataLane | $22,500,000 | (Dec 18, 2025)
Addition Therapeutics | $100,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)
Scylos | $3,000,000 | (Dec 18, 2025)
Last Energy | $100,000,000 | (Dec 18, 2025)
Navier AI | $6,500,000 | (Dec 17, 2025)
Verisoul | $8,800,000 | (Dec 17, 2025)
Aeovian Pharmaceuticals | $55,000,000 | (Dec 17, 2025)